Page 12 - GPD-2-2

Gene & Protein in Disease MOR in cancer

Table 1. Relationship between MOR and different types of cancer
Tumors Drugs Effects Mechanism Signaling Result Conclusion References
(Opioids) pathway
HCC Morphine Tumor The activation of MOR [19]
suppressor specifically failed to
suppress the malignant
phenotype of the tumor
Pancreatic cancer Morphine Tumor Tumor MOR overexpression MOR was expressed in [118]
promoter proliferation, increased proliferation in pancreatic cancer and
invasion pancreatic cancer cells might be involved in
tumor progression and
chemoresistance
Colorectal cancer Uncertain Tumor cAMP/PKA There were differences in the The overall expression [119]
proliferation expression of MOR in tumor of MOR increased in
and control tissues colorectal cancer
HCC Xanthomicrol Tumor Tumor Xanthomicrol inhibited the Xanthomicrol is a potential [55]
promoter migration migration and invasion of MOR antagonist, with
and invasion Huh7 cells potent anti-migration and
anti-invasion ability on
Huh7 cells
Breast cancer Tumor Tumor GSK3 Opioid and beta-adrenergic Screening for ligands [120]
suppressor proliferation receptors were shown to targeting B2AR and MOR
cross talk through formation interaction and/or the
of receptor heterodimers GSK3 system may help in
to control the growth and identifying novel drugs for
proliferation of breast cancer the prevention of triple-
cells negative breast cancer cell
growth and metastasis
Cervical cancer Morphine and Tumor Immune JAK3/ The combination of Morphine-ketamine [84]
ketamine promoter function STAT5 morphine and ketamine combination could
might decrease CD4 + improve cancer pain and
percentage, CD4 /CD8 repress immune function
+
+
ratio, and the levels of via the JAK3/STAT5
cytokines through the JAK3/ pathway in the progression
STAT5 pathway of cervical cancer
Glioblastoma Pethidine Tumor Blocks NADH, hinder mitochondrial respiration, enhance Pethidine could inhibit [121]
suppressor the pro-autophagic and pro-apoptotic ceramide levels in tumor progression
cancer cells
HCC mAb Tumor Tumor CD147/p53 Higher expression of MOR has the potential to [56]
promoter proliferation MAPK MOR in HCC cells than in be a therapeutic target to
adjacent tissue treat HCC
CRC Morphine and Tumor Tumor ERK1/2, Morphine promoted Morphine might be a [122]
cetuximab promoter proliferation, AKT- tumorigenesis and promising therapeutic
migration, mTOR, cetuximab resistance target for CRC patients,
invasion, RAS-MAPK through activation of EGFR especially for cetuximab-
and drug signaling in human CRC resistant CRC patients
resistance
NSCLC Morphine Tumor Tumor MOR/Src/ Morphine enhanced cell Morphine promoted [123]
promoter proliferation, mTOR migration and invasion the malignant biological
migration, behavior of H460 cells by
invasion activating MOR and Src/
mTOR signaling pathways

(Cont’d....)

Volume 2 Issue 2 (2023) 6 https://doi.org/10.36922/gpd.282